Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).

Antimicrobial Agents and Chemotherapy
Michelle NelsonAndrew J H Simpson

Abstract

Pharmacokinetic and efficacy studies with levofloxacin were performed in the common marmoset (Callithrix jacchus) model of inhalational tularemia. Plasma levofloxacin pharmacokinetics were determined in six animals in separate single-dose and multidose studies. Plasma drug concentrations were analyzed using liquid chromatography-tandem mass spectrometry-electrospray ionization. On day 7 of a twice-daily dosing regimen of 40 mg/kg, the levofloxacin half-life, maximum concentration, and area under the curve in marmoset plasma were 2.3 h, 20.9 microg/ml, and 81.4 microg/liter/h, respectively. An efficacy study was undertaken using eight treated and two untreated control animals. Marmosets were challenged with a mean of 1.5 x 10(2) CFU of Francisella tularensis by the airborne route. Treated animals were administered 16.5 mg/kg levofloxacin by mouth twice daily, based on the pharmacokinetic parameters, beginning 24 h after challenge. Control animals had a raised core body temperature by 57 h postchallenge and died from infection by day 5. All of the other animals survived, remained afebrile, and lacked overt clinical signs. No bacteria were recovered from the organs of these animals at postmortem after culling at day 24 postchallen...Continue Reading

References

Nov 1, 1992·The Journal of Infectious Diseases·D J KellyA M Friedlander
Jun 1, 1985·Felʹdsher i akusherka·V E Poliakov
Jan 11, 1985·JAMA : the Journal of the American Medical Association·A B KaiserM E Evans
Sep 1, 1969·The Journal of Hygiene·H A Druett
Mar 1, 1997·Journal of Pharmaceutical and Biomedical Analysis·F A WongS C Flor
Oct 23, 1997·Antimicrobial Agents and Chemotherapy·S C ChienA T Chow
Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A P Limaye, C J Hooper
Apr 25, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E A Aranda
Jun 21, 2001·JAMA : the Journal of the American Medical Association·D T DennisUNKNOWN Working Group on Civilian Biodefense
Mar 20, 2002·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control and Prevention (CDC)
Oct 5, 2002·Clinical Microbiology Reviews·Jill EllisRichard W Titball
Oct 16, 2004·Expert Review of Anti-infective Therapy·Douglas N Fish
Jul 26, 2006·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·A HemeryckM F Kelley
Apr 3, 2008·Expert Review of Anti-infective Therapy·Matthew J Hepburn, Andrew J H Simpson
May 8, 2008·International Journal of Experimental Pathology·Mark S LeverMark J Fulop
Apr 2, 2009·International Journal of Experimental Pathology·Michelle NelsonAndrew J H Simpson
Apr 10, 2009·International Journal of Clinical Pharmacology and Therapeutics· M, F J Flores-Murrieta
Oct 28, 2009·Antimicrobial Agents and Chemotherapy·Fang LiChristoffer W Tornoe

❮ Previous
Next ❯

Citations

Jun 29, 2011·Future Microbiology·Mitali Sarkar-Tyson, Helen S Atkins
May 3, 2011·International Journal of Antimicrobial Agents·Michelle NelsonMark S Lever
Apr 16, 2014·Frontiers in Cellular and Infection Microbiology·Sandrine BoissetMax Maurin
Dec 6, 2014·International Journal of Experimental Pathology·Michelle NelsonMark S Lever
Apr 4, 2021·Vaccines·Mark J PrescottAmy C Shurtleff
May 9, 2021·Research in Veterinary Science·Andrejs SitovsMario Giorgi
Jun 1, 2021·Frontiers in Microbiology·Stephen J Kassinger, Monique L van Hoek

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.